Adult Neuromuscular Neurologist; Director, Calgary Neuromuscular Program
Associate Professor, Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary
NMD4C Working Group(s): Clinical Trial Coordination, Patient RegistriesEmail Lawrence
Dr. Lawrence Korngut is a neurologist, clinical neurophysiologist and Director of the Calgary Neuromuscular Program and the Calgary ALS and Motor Neuron Disease Clinic. His research includes phase II and III clinical trials of new therapies for neuromuscular conditions. He is the National Principal Investigator of the Canadian Neuromuscular Disease Registry that now includes 31 participating clinics and over the past ten years has recruited over 4400 patients.
Dr. Korngut is the National Principal Investigator of the CNDR, and former Chair of the Canadian Neuromuscular Diseases Network (CAN-NMD), which was funded by the Canadian Institutes of Health Research and Muscular Dystrophy Canada in 2014 and consists of a nationwide collaboration of researchers, clinicians, and allied health professionals aiming to improve the lives those affected by neuromuscular conditions through improving clinical care, research capacity and education. He is the former Chair of the Medical and Scientific Advisory Committee and served on the Board of Directors of Muscular Dystrophy Canada.
Dr. Korngut completed his undergraduate degree in Life Sciences at Queen’s University (Kingston, Canada), medical school and neurology residency at Western University (London, Canada), neuromuscular clinical and research fellowship and Masters of Science in Clinical Epidemiology at the University of Calgary, Alberta, Canada. He serves as the Director of Innovation and Commercialization at the Hotchkiss Brain Institute.
Within NMD4C Dr. Korngut will bring in his experience of Canadian networking in CAN-NMD and participates in the network’s work in trial capacity building.
Statland, JM, Campbell, C, Desai, U, Karam, C, Díaz-Manera, J, Guptill, JT et al.. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2022. PMID:35428982
McMillan, CT, Wuu, J, Rascovsky, K, Cosentino, S, Grossman, M, Elman, L et al.. Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches. Amyotroph Lateral Scler Frontotemporal Degener. 2022. 1-10 PMID:35253557
Tanchip, C, Guarin, DL, McKinlay, S, Barnett, C, Kalra, S, Genge, A et al.. Validating Automatic Diadochokinesis Analysis Methods Across Dysarthria Severity and Syllable Task in Amyotrophic Lateral Sclerosis. J Speech Lang Hear Res. 2022.65 (3)940-953 PMID:35171700
Ishaque, A, Ta, D, Khan, M, Zinman, L, Korngut, L, Genge, A et al.. Distinct patterns of progressive gray and white matter degeneration in amyotrophic lateral sclerosis. Hum Brain Mapp. 2022.43 (5)1519-1534 PMID:34908212
Cudkowicz, M, Genge, A, Maragakis, N, Petri, S, van den Berg, L, Aho, VV et al.. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2021.20 (10)821-831 PMID:34536404See more on PubMed